Baseline characteristics of people starting warfarin therapy after atrial fibrillation was diagnosed
| Characteristic | Patients, no. (%)* n = 125 195 |
|---|---|
| Age at start of study, yr, median (IQR) | 77 (72–82) |
| Age category, yr | |
| 66–75 | 53 260 (42.5) |
| 76–85 | 56 026 (44.8) |
| ≥ 86 | 15 909 (12.7) |
| Male sex | 61 911 (49.5) |
| Income quintile | |
| 1 | 24 945 (19.9) |
| 2 | 27 033 (21.6) |
| 3 | 24 707 (19.7) |
| 4 | 23 401 (18.7) |
| 5 | 24 752 (19.8) |
| Missing | 357 (0.3) |
| Rural residence | 18 942 (15.1) |
| Charlson comorbidity index | |
| 0 | 36 616 (29.2) |
| 1 | 26 397 (21.1) |
| ≥ 2 | 39 919 (31.9) |
| No admission to hospital | 22 263 (17.8) |
| Drugs prescribed in past 1 yr, no., median (IQR) | 8 (5–12) |
| Previous admission to hospital for hemorrhage | 5 596 (4.5) |
| Resident of long-term care facility | 6 411 (5.1) |
| Comorbidity (past 3 yr) | |
| Renal disease | 1 876 (1.5) |
| Liver disease | 3 873 (3.1) |
| Alcoholism | 3 801 (3.0) |
| Dementia | 11 831 (9.5) |
| Medication use (past 120 d) | |
| Acetylsalicylic acid | 24 328 (19.4) |
| Acetylsalicylic acid and clopidogrel | 557 (0.4) |
| Acetylsalicylic acid and dipyridamole | 817 (0.7) |
| Other nonsteroidal anti-inflammatory drugs | 20 671 (16.5) |
| Clopidogrel | 4 151 (3.3) |
| Ticlopidine | 1 092 (0.9) |
| Time to starting warfarin therapy, d, median (IQR) | 7 (2–22) |
| 0 | 21 573 (17.2) |
| 1–7 | 41 278 (33.0) |
| 8–14 | 21 090 (16.8) |
| 15–30 | 16 976 (13.6) |
| 31–100 | 24 278 (19.4) |
| CHADS2 score (components) | |
| Congestive heart failure | 44 011 (35.2) |
| Hypertension | 94 063 (75.1) |
| Age > 75 yr | 78 408 (62.6) |
| Diabetes | 30 437 (24.3) |
| Previous stroke | 26 661 (21.3) |
| CHADS2 score | |
| 0 | 8 655 (6.9) |
| 1 | 30 108 (24.0) |
| 2 | 44 716 (35.7) |
| 3 | 29 713 (23.7) |
| 4 | 9 599 (7.7) |
| 5 | 1 860 (1.5) |
| 6 | 544 (0.4) |
Note: IQR = interquartile range.
↵* Unless otherwise indicated.